Informational Boards in the changing landscape of Medical Affairs

MA

Guest article by Anabela Farrica

The Medical Diplomacy (MA) office is known to be a rather broad and hard one to define. (1)  Its operations are substantially founded on the scientific exchange with internal and external stakeholders, with the ultimate goal of translating medical science into value – not only value for the business organization, but too, and virtually importantly, value for the patient through an adequate and safe use of their products. The methods MA groups employ to support and fulfill this goal are of great diverseness: scientific congress support; informational board realization; data generation (by providing support to both pre- and postal service-marketing studies); implementation of educational programmes for healthcare professionals (HCP) and patients; promotional fabric review; providing answers to medical enquiries; and many others. (ii)

The success of a MA group is highly dependent upon the understanding, by its members, of how the regulations surrounding their activities use and, at the same fourth dimension, of the commercial implications of their piece of work. (1) Maintaining this fragile remainder is no small task, especially considering the intensified public and regulatory scrutiny applied to the pharmaceutical and medical device industries. (3)

Furthermore, the job of MA has become increasingly complex, not only because of this scrutiny on the industry, but likewise considering there is a host of external challenges that increases the expectations for these professionals:

  • HCP's data needs have grown and become more demanding; (4)
  • A sharper focus on Risk Management; (five)
  • The growing prevalence of chronic diseases; (5)
  • An increased industry focus on niche diseases, with products characterized past a larger amount of circuitous scientific information; (5)
  • The emergency of new types of data (e.g. Existent World Data) and an expanding number of its users; (6)
  • A rise in digital media as sources of medical information that have made patients a pivotal stakeholder in today's industry communication initiatives. Specifically, at that place is a growing interest on the patient's satisfaction as a consumer of care. (5)
  • A more than demanding market access environment, with strict pricing and reimbursement policies that difficult admission to the often costly therapeutic novelties. (5)

Additionally, the focus of a MA team on the sound scientific interpretation of drug-specific and data-specific information and its implications has been recognized by the companies has a valuable asset for strategic planning. In this role, the MA professionals have become crucial by helping to bridge science with commercial aspirations. (6)

In the confront of these challenges, MA's purpose of enhancing medical care will not only crave a deep comprehension of production cognition, merely also a robust, informed view of the needs, requirements, expectations and perspectives of diverse healthcare stakeholders. (seven) Advisory boards, while non a novelty for MA teams, are of detail relevance as a strategy for obtaining not-bounden only informed guidance on a range of business concern aspects. (8)

Advisory boards are normally held with Central Opinion Leaders (KOLs) in the company's fields of expertise in order to obtain expert feedback on various aspects related to a product or disease state. (2) An constructive advisory board is a precious tool to gain insights on possible research opportunities, including guidance on clinical evolution and trial protocols, as well as unmet medical needs that might drive future clinical strategies. Input on marketing strategies, plans or materials can too be acquired through these meetings. (2, 7) By allowing a direct date with the medical community, advisory boards help pharmaceutical companies in product development, data generation, strategy refinement and in creating relevant and reliable educational and promotional content. (7)

Advisory boards tin, thus, have place virtually at any stage of production evolution, depending on the needs identified by the visitor. However, equally the regulatory requirements go tougher and payers look for ever more clear-cut proof of products' value, MA should seek out to include insights from a broad range of external medical conclusion-makers and influencers into early on clinical development. (vii, ix) Expert input might guide, for instance, the run a risk management plan for clinical trials and the identification of the ideal target groups for the product, to ensure optimal clinical outcome is achieved. The importance of this input grows as the a product moves along the development and regulatory pathways – especially as information technology progresses onto Phase III or Pivotal Clinical Trials, which are frequently determinants of production success. It might be benign to taken this type of advice from both Global and Regional advisory boards, to accept into business relationship regulatory and clinical differences, or fifty-fifty physiological variations between populations. (10)

Once a drug is licenced, advisory boards might be useful to: (2)

  • Understand the appropriateness and effectiveness of marketing strategies;
  • Place and design the necessary post-marketing clinical trials;
  • Perfect the medical and/or patient education measures that have been adopted;
  • Increase understanding of how satisfied physicians and patients are with the product and of how to all-time fill up in the gaps and voids that may exist.

A successful advisory board is 1 that generates actionable deliverables and that fosters positive relationships with prominent members of the scientific community. (7) The trend for tighter budgets and the pressure to do more for less stand for bang-up challenges to MA professionals. To maximize the render on investment, it is important to invest optimal resources in structuring an advisory board appropriately. (eight) Cost reduction should not hateful that meeting quality is compromised, as poorly executed advisory boards fail to provide companies with instructive medical insights and added-value recommendations from the medical experts in attendance. (7) Some of the elements to consider in an advisory board to ensure the desired outcomes are:

  1. Have a clear objective: the MA team responsible for organizing the advisory board must set a focused goal that non only justifies holding the meeting, just volition besides determine its members and guide the discussion. (11)
  2. Choose the right people: ideally, the grouping of advisors should exist representative of the multifariousness of skills, expertise and experience related to the specific topic under discussion. This means that the board should not necessarily consist of product supporters only, for example. In some cases, the best insights and ideas come up when opinions diverge. (7) Having members that are good communicators and are open-minded is also important to foster word. "Big names" can be a powerful addition to an advisory board, but an uneven peer group, with a mixture of elements with various levels of notoriety or responsibility, may create barriers instead of opportunities. (12)
  3. Clarify expectations: when inviting an adept to bring together an advisory lath, information technology is essential to lay down the expectations the MA team has for the meeting in terms of fourth dimension, areas where help is beingness sought out and finish consequence. If the object of give-and-take includes private information, members should be notified of the need to sign a confidentiality understanding. (12)
  4. Recoup the participants: money should not exist the main motivator for participation in an advisory board. All the same, it is good grade to provide some sort of compensation, such as meals, travel expenses or even a small fee. Members that feel appreciated will be more willing to engage in active word. (12)
  5. Brand sure board members are prepared: distributing data to board participants before the meeting increases the chances of an interactive, successful meeting. (11) Pre-readings or other materials ensures that all participants are equally prepared, thus facilitating the flow of the session and promoting an active and open participation by the group.
  6. Assign a great moderator: preferably a person from the MA team that is familiar with the details of the effect for which input is existence nerveless. This helps energizing the meeting onto an terminate event that is effective and actionable. (vii)
  7. Organize the meeting appropriately: from a member-driven agenda that stimulates interest to a meeting location that is comfortable and free of distraction, a carefully thought out meeting is essential to maximize potential benefits. (12)
  8. Diversify the communication methods: typical Powerpoint presentations may not work for everyone, due to the natural heterogeneity in learning and group discussion styles. Handouts with relevant graphics, videos or questionnaires are interesting alternatives to consider. (vii)
  9. Assess the meeting: obtain feedback immediately after an informational board ends. Self-assessment and monitoring are key. (eleven)
  10. Convert meeting results into action steps: in club for the cadre objective of the advisory board to be fulfilled, the insights gained from the coming together should be capitalized nether the form of practical visitor activities. (7) A board where the solicited feedback results in activity steps is a successful lath. (2)
  11. Follow-up with board participants: keeping the members of the advisory board informed on the outcomes of the meeting is vital to foster connected scientific exchange with these KOLs. Updates on what is being planned and on what the visitor has worked on as a consequence of the coming together should be made on a regular basis.

These practices ensure advisory boards are founded on professional dialogue and informative feedback, which can assistance identify cardinal issues needing clarity or exploration and set a framework for value-added change. (13)

In the (contempo) past, the biopharmaceutical industry was under a considerable amount of criticism effectually the unduly utilise of allegedly scientific advisory boards every bit promotional events to influence physician'due south prescribing habits. Accusations of promotion of either unlicensed products or indications emerged, too as suspicions of disproportional compensation and hospitality given the nature of the meetings. Present, these and other types of interactions between the industry and healthcare professionals are governed by a set of rules: European and/or national law; companies' Codes of Bear; and ethical standards defined past EFPIA and by national associations of the pharmaceutical industry (APIFARMA, in Portugal) that accept been increasingly advocating for a culture of transparency. (10)

Advisory boards have been a part of the MA landscape for a long time, functioning as sources of expert insight into a wide range of problems related to products' lifecycle.  Today, they are more useful than ever, as regulatory requirements get tougher and patients, payers and healthcare providers need more and more diverse clinical data and wellness outcomes information to show production vale. Effectively managed informational boards assistance MA teams to achieve this and more – as the ultimate goal of the knowledge gained should always be to improve the quality of life for patients. Biopharmaceutical companies are expected to seek and use innovative ways of conducting informational boards and capitalizing on the wisdom gained, so as to balance the value added to their clinical and commercial goals with the compliance with the relevant codes and laws.

References

  1. Wolin MJ, Ayers PM, Chan EK. The Emerging Role of Medical Affairs within the Modernistic Pharmaceutical Company. Drug Information Journal. 2001;35(2):547-55.
  2. Evens R. Medical Affairs and Professional person Services. In: Evens R, editor. Drug and Biological Development: Springer US; 2007. p. 240-74.
  3. Werling; M, Carnell; H, McCormick; D, LLP; M, Chicago I. Focus on Life Science Compliance: The Evolution of Medical Affairs Departments. AHLA Connections. 2011;15(11).
  4. Bloom; 50, Andre; T, Chandran; P, Dabbs; E, Keen. Chiliad. Raising the Bar in Biopharma Medical Affairs: 3 Critical Success Factors Boston Consulting Groups: Boston Consulting Groups; 2013 [cited 2015 27-06-2015]. Available from: https://www.bcgperspectives.com/content/articles/biopharmaceuticals_raising_the_bar_in_biopharma_medical_affairs/.
  5. Morgon P. Medical Diplomacy. CEGEDIM, 2014.
  6. Evers; One thousand, Fleming; E, Ghatak; A, Hartmann; J, Nathoo; A, Piervincenzi; R, et al. Pharma Medical Diplomacy 2020 and beyond. McKinsey & Company: McKinsey & Company, 2012.
  7. Dyer; S, Tolmachev. A. Nine Central Elements To Ensure Advisory Lath Success pm360online: pm360online; 2014 [cited 2015 27-06-2015].
  8. Best Practices L. New Study Presents Insights to Advisory Board Effectiveness in the Pharmaceutical Sector prnewswire.com: prnewswire.com; 2015 [cited 2015 27-06-2015]. Bachelor from: http://www.prnewswire.com/news-releases/new-study-presents-insights-to-advisory-board-effectiveness-in-the-pharmaceutical-sector-300076091.html.
  9. Presson J. ADVISORY BOARD FUNCTIONS EXPANDING IN PHARMA Industry Cut Edge Information: Cutting Edge Information; 2013 [cited 2015 27-06-2015]. Bachelor from: https://www.cuttingedgeinfo.com/2013/advisory-board-functions-expanding-pharma-industry/.
  10. Liftstream. Scientific Informational Boards and the Impact of Compliance Liftstream: Liftstream; 2015. Bachelor from: http://www.liftstream.com/blog/scientific-informational-boards-and-the-impact-of-compliance/#.
  11. Moltz B. x Steps To Forming An Effective Advisory Board American Express American Express 2011 [cited 2015 27-06-2015]. Available from: https://www.americanexpress.com/us/pocket-sized-business/openforum/articles/10-steps-to-forming-an-effective-advisory-board-1/.
  12. Stengel M. Ten Tips to Creating an Effective Advisory Board Stengel Solutions: Stengel Solutions; 2003 [cited 2015 27-06-2015]. Available from: http://www.stengelsolutions.com/tips19.htm.
  13. Joyce D. Medical Affairs: The Catalyst for Constructive Medical Communications. PharmaVOICE. 2013:46-7.
  • advisory
  • advisory boards
  • diplomacy
  • Anabela Farrica
  • APIFARMA
  • boards
  • clinical trials in portugal
  • efpia
  • ensaios clinicos em portugal
  • farmaceutica
  • industria
  • manufacture
  • management
  • marcio
  • medical
  • medical affairs
  • medical department
  • multiple sclerosis
  • pharmaceutical
  • pharmaceutical manufacture
  • pharmaceutical manufacture internship
  • pharmaceutical medicine
  • Pharmaupdates
  • Pharmupdate
  • Portugal
  • Portugal medicines
  • risk
  • risk management
  • sales
  • sales strength